Glucocorticoid receptor antagonism by cyproterone acetate and RU486
| Autor: | Steele Ronald Edward, Ricardo E. Chatelain, Wendy D. Cornell, Christian Honer, Gary Michael Ksander, Robert Schweitzer, Kiyean Nam, Marshall Paul James, Christoph Schumacher, Cynthia A. Fink |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class Pharmacology Antiandrogen Ligands Rats Sprague-Dawley chemistry.chemical_compound Transactivation Glucocorticoid receptor Drug Delivery Systems Receptors Glucocorticoid Internal medicine medicine Animals Humans Cyproterone Acetate Transrepression Chemistry Cyproterone acetate Androgen Antagonists Rats Mifepristone Endocrinology Nuclear receptor Molecular Medicine Cyproterone Receptors Progesterone Progestin medicine.drug |
| Zdroj: | Molecular pharmacology. 63(5) |
| ISSN: | 0026-895X |
| Popis: | The steroid compound cyproterone acetate was identified in a high-throughput screen for glucocorticoid receptor (GR) binding compounds. Cyproterone (Schering AG) is clinically used as an antiandrogen for inoperable prostate cancer, virilizing syndromes in women, and the inhibition of sex drive in men. Despite its progestin properties, cyproterone shares a similar pharmacological profile with the antiprogestin mifepristone (RU486; Roussel Uclaf SA). The binding affinities of cyproterone and RU486 for the GR and progesterone receptor were similar (K(d), 15-70 nM). Both compounds were characterized as competitive antagonists of dexamethasone without intrinsic transactivating properties in rat hepatocytes (K(i), 10-30 nM). In osteosarcoma cells, RU486 revealed a higher potency than cyproterone acetate to prevent responses to dexamethasone-induced GR transactivation and NF kappa B transrepression. Upon administration to Sprague-Dawley rats, both compounds were found to be orally bioavailable and to inhibit transactivation of liver GR. Molecular docking of cyproterone acetate and RU486 into the homology model for the GR ligand binding domain illustrated overlapping steroid scaffolds in the binding pocket. However, in contrast to RU486, cyproterone lacks a bulky side chain at position C11 beta that has been proposed to trigger active antagonism of nuclear receptors by displacing the C-terminal helix of the ligand-binding domain, thereby affecting activation function 2. Cyproterone may therefore inhibit transactivation of the GR by a molecular mechanism recently described as passive antagonism. New therapeutic profiles may result from compounds designed to selectively stabilize the inactive and active conformations of certain nuclear receptors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|